Diben For patients with impaired glucose metabolism
Why choose Noble Healthcare Products?
- European Made – the latest technology
- Australian owned 100%
- Free Freight for orders over $300
- Free returns of unused disposable products up to 12 months
- Real Support – Speak to us in person
Registered NDIS clients receive a 10% discount on the disposable continence range *
Enjoy Our Bonus Reward Scheme!
Contact us to find out about our rewards system.
‘Earn while you spend’
Lowest price guaranteed for disposable nappies, pants and pads *
Please provide a written quote for an equivalent product and we will match it
Send to – firstname.lastname@example.org
1 kcal/ml 22.5 g protein
For the dietary management of patients with or at risk of malnutrition with impaired glucose metabolism such as in impaired glucose tolerance, stress-induced hyperglycaemia, diabetes mellitus.
Available in 500 ml EasyBag.
- Energy: 1.05 kcal/mL - 525 kcal per 500mL bag
- Protein: 22.5g per 500mL bag
- With fibre
- With clinical evidence from multicentre trial demonstrating positive long-term effects on nutritional parameters1,2 relevant for the target group
- Modified carbohydrate profile: With low glycaemic index for improved glycaemic control3,4
- Adapted fat profile:
High in MUFA contributes to improve glycaemic control5-7 and insulin sensitivity8-10
With fish oil according to recommendation for cardiovascular diseases* as XY% of diabetic patients have additional cardiovascular problems**
- Increased chromium helps to improve insulin sensitivity14
1) Pohl M, Mayr P, Mertl-Roetzer M, et al. Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids: a randomised controlled trial. Eur J Clin Nutr. 2005;59(11):1221-1232.
2) Pohl M, Mayr P, Mertl-Roetzer M, et al. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial. JPEN. 2009;33(1):37–49.
3) Thomas DE & Elliott EJ. The use of low-glycaemic index diets in diabetes control. Br J Nutr. 2010;104(6):797-802.
4) Barazzoni R, Deutz NE, Biolo G, et al. Carbohydrates and insulin resistance in clinical nutrition: Recommendations from the ESPEN expert group. Clin. Nutr. 2017;36(2): 355-363.
5) Pohl M, Mayr P, Mertl-Roetzer M, et al. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial. JPEN. 2009;33(1):37–49.
6) Lochs H, Allison SP, Meier R, et al. Introductory to the ESPEN Guidelines on Enteral nutrition: terminology, definitions and general topics. Clin Nutr. 2006;25(2):180–186.
7) Qian F, Korat AA, Malik V,et al. Metabolic effects of monounsaturated fatty acid–enriched diets compared with carbohydrate or polyunsaturated fatty acid–enriched diets in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):1448–1457.
8) Paniagua JA, De La Sacristana AG, Romero I, et al. Monounsaturated fat–rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care. 2007;30(7):1717-1723.
9) Brehm BJ, Lattin BL, Summer SS, et al. One-year comparison of a high–monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care. 2009;32(2):215–220.
10) Gadgil MD, Appel LJ, Yeung E, et al. The Effects of Carbohydrate, Unsaturated Fat, and Protein Intake on Measures of Insulin Sensitivity. Diabetes Care. 2013;36(5):1132-1137.
11) Kris-Etherton PM, Grieger JA, Etherton TD. Dietary reference intakes for DHA and EPA. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2009;81(2-3):99-104.
12) International Society for the Study of Fatty Acids and Lipids (ISSFAL): Recommendations for Dietary Intake of Polyunsaturated Fatty Acids in Healthy Adults. Report June 2004.
13) Lee JH, O'keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332
14) Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta‐analysis of the efficacy and safety of chromium supplementation in diabetes. J. Clin Pharm Ther 2014;39(3):292-306.
ALLERGENS: This product contains milk, soy and and fish oil.